Six months multicentre pilot open label single-arm study to evaluate patient experience, acceptability and satisfaction of switching certolizumab pegol from a prefilled syringe or autoinjection pen to an AVA® e-Device in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis patients.
Joaquín Borrás BlascoEsther Vicente-EscrigFrancisco José Rodríguez-LucenaAna García-MonsalveElena Arroyo-DomingoRaul Ferrando-PiqueresElvira CasteráAndrés Navarro-RuizPublished in: Journal of clinical pharmacy and therapeutics (2022)
The AVA® is an advantageous delivery option for CZP in patients with RA, PsA, axSpA.
Keyphrases
- rheumatoid arthritis
- disease activity
- open label
- end stage renal disease
- ankylosing spondylitis
- prostate cancer
- study protocol
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- randomized controlled trial
- cross sectional
- interstitial lung disease
- squamous cell carcinoma
- radiation therapy
- phase ii study